Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 7/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21391475 | 0.81 | EPHX2 (0.42) | EPHX2MEN1THRBHTTKMT2A | |
| SCHEMBL10784050 | 0.81 | EPHX1 (0.58) | MEN1KMT2AEPHX1 | |
| SCHEMBL24508760 | 0.79 | CES2 (0.52) | EPHX2CES2MEN1THRBHTT | |
| SCHEMBL25698945 | 0.79 | MEN1 (0.43) | EPHX2MEN1KMT2AMAPTACHE | |
| SCHEMBL23696416 | 0.78 | MEN1 (0.46) | EPHX2MEN1KMT2AMAPTTLR2 | |
| SCHEMBL25477658 | 0.78 | MEN1 (0.46) | EPHX2MEN1KMT2AMAPTTLR2 | |
| SCHEMBL24379955 | 0.78 | MEN1 (0.46) | EPHX2MEN1KMT2AMAPTTLR2 | |
| SCHEMBL22790662 | 0.78 | MEN1 (0.44) | EPHX2MEN1KMT2ATLR2 | |
| SCHEMBL22802925 | 0.78 | CES2 (0.50) | EPHX2CES2MEN1THRBHTT | |
| SCHEMBL21342537 | 0.78 | MEN1 (0.40) | EPHX2MEN1KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EPHX2 1890/4885CES2 1669/4885MEN1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.